A case of bullous dermatitis induced by erlotinib.
Oncologist
; 14(12): 1201-4, 2009 Dec.
Article
em En
| MEDLINE
| ID: mdl-19965913
ABSTRACT
Herein, we report a case of bullous dermatitis that occurred in a 61-year-old woman 5 days after beginning therapy with erlotinib for the treatment of stage IV pulmonary adenocarcinoma with metastases at the hypophyseal level. Skin reactions are the most common adverse drug reactions (ADRs) associated with epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors, and acneiform rash is the most frequently reported ADR in patients treated with erlotinib. To our knowledge, this is the first case of bullous dermatitis induced by erlotinib. This report highlights the need for additional research in the field of skin toxicity of EGFR-TK inhibitors.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Quinazolinas
/
Dermatopatias Vesiculobolhosas
/
Toxidermias
/
Dermatite
Limite:
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article